Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Orasure Technologies (EP3) AI Stock Analysis

DE:EP3

Orasure Technologies

(Frankfurt:EP3)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong liquidityThe combination of $161 million in cash and zero debt gives OraSure meaningful financial flexibility over the next several quarters. This liquidity can fund product launches, regulatory work, and operating needs without immediate reliance on borrowing, while reducing balance-sheet stress during the recovery.
Negative Factors
Severe revenue and profitability declineThe sharp TTM revenue contraction and deeply negative operating and net margins show that OraSure’s current expense base is not aligned with its reduced sales level. This weak earnings profile limits internal funding capacity and makes a durable recovery dependent on renewed demand and cost improvement.

Orasure Technologies (EP3) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%DE:EP3+56.76%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 271.74M
Dividend Yield
―
Average Volume (3M)
1,093
Price to Earnings (P/E)
-5.7
Beta (1Y)
0.42
Revenue Growth
-24.36%
EPS Growth
6.12%
Country
Germany
Employees
500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Orasure Technologies Business Overview & Revenue Model

Company Description

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, E...

Orasure Technologies Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-1.69%|Next Earnings Date:Nov 08, 2026
Earnings Call SentimentPositive

The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.

Positive Updates

Revenue Growth and Guidance
Total revenue of $30.6M in Q2 2026, exceeding guidance and growing 9.7% sequentially; Q3 2026 revenue guidance of $29.5M–$32.5M.

Negative Updates

IntelliQ (CT/NG) Regulatory Delay
Company withdrew FDA submission for the IntelliQ CT/NG rapid molecular self‑test on the SHERLOQ platform after constructive FDA interactions; management no longer expects U.S. clearance and launch in 2026 and timing for resubmission/clearance is unconfirmed.

Company Guidance

OraSure guided Q3 revenue of $29.5 million to $32.5 million with gross margin expected to be similar to Q2 (Q2 GAAP gross margin 43.5% and non‑GAAP gross margin 44.2%), reiterating full‑year 2026 revenue growth and a target of operating cash‑flow breakeven entering 2027; for context Q2 revenue was $30.6 million (up 9.7% sequentially) with Diagnostics $19.4 million (up 14.7% seq.) and SMS $9.9 million (up 9% seq.), Q2 operating cash flow was negative $9.9 million, GAAP operating income was $5.4 million (non‑GAAP operating loss $14.7 million), R&D was $9.4 million, S&M $6.6 million, G&A $14.4 million, non‑cash stock comp $2.3 million, D&A $2.4 million; balance sheet and capital notes included $161 million cash, zero debt, $2 million of share repurchases in Q2 (647k shares), $22 million returned year‑to‑date (7.7M shares, ~10% of shares; ~55% of a $40M authorization), a pause on buybacks to preserve flexibility for Colli‑Pee and Ebola 2.0 launch investments, an expected decline in G&A as nonrecurring items wind down, and a reduced contingent consideration liability tied to the IntelliQ resubmission plan.

Orasure Technologies Risk Analysis

Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Orasure Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:EP3 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
INFUINFU79Outperform$280.23M33.4814.81%―2.47%75.23%
UTMDUTMD75Outperform$216.06M20.378.78%1.82%-9.62%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SMTISMTI46Neutral$301.64M-8.83-473.55%―12.93%-219.19%
STXSSTXS44Neutral$86.43M-3.49-132.62%―-5.47%13.55%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:EP3INFUSTXSUTMDMBOTSMTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:EP3 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:EP3Orasure3.481.2052.63%
INFUInfuSystem Holdings, Inc.14.073.6735.29%
STXSStereotaxis0.86-1.92-68.99%
UTMDUtah Medical Products68.0810.6918.63%
MBOTMicrobot Medical1.09-1.03-48.58%
SMTISanara MedTech32.833.8413.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.